Secukinumab versus guselkumab in the complete treatment of ustekinumab‑resistant psoriatic plaques: ARROW

To investigate the clinical and molecular effects of direct IL-17A versus selective IL-23 inhibition in patients with anti-IL-12/23 refractory psoriatic plaques. A 16-week, randomized, open-label, parallel-group, phase 2a multicenter study (ARROW) was conducted in patients presenting with ≥1 active psoriatic plaque (total clinical score [TCS] ≥6) at screening despite adequate treatment with ustekinumab (label dose ≥24 weeks) and with a Psoriasis Area Severity Index (PASI) score 1–10. Patients were randomized 1:1 to receive secukinumab 300 mg (n=20) or guselkumab 100 mg (n=20). Descriptions: BL = Baseline W16 = 16 weeks of treatment NL = non-lesional skin LS = lesional skin